Recent Updates on Transdermal Drug Delivery Approaches for the Management of Gout and its Clinical Perspective


Cite item

Full Text

Abstract

Oral and injectable drug administration have recently been replaced with transdermal drug delivery (TDD) approaches, which are less intrusive, less likely to be rejected by patients, and easier to administer. There is still room for improvement in the treatment of gout with the use of a TDD system. Gout has become a worldwide epidemic and a severe threat to human beings. Gout treatment can be accomplished in various ways, including orally and intravenously. Several traditional options are still useless, cumbersome, and potentially dangerous. Hence, gout therapeutic options are desperately required for more effective and less toxic drug delivery methods. Antigout medications using TDD could substantially influence obese people in the future, even if most trials are still in the animal stages. Thus, this review aimed to provide a concise overview of recent TDD technologies and anti-gout medication delivery methods that improved therapeutic efficacy and bioavailability. Moreover, clinical updates on investigational drugs have been discussed to address the potential findings against gout.

About the authors

Ranjit Harwansh

Institute of Pharmaceutical Research, GLA University

Author for correspondence.
Email: info@benthamscience.net

Soumya Mishra

Institute of Pharmaceutical Research, GLA University

Email: info@benthamscience.net

Rupa Mazumder

Institute of Pharmacy,, Noida Institute of Engineering and Technology

Email: info@benthamscience.net

Rohitas Deshmukh

Institute of Pharmaceutical Research, GLA University

Email: info@benthamscience.net

Akhlaquer Rahman

Department of Pharmaceutics, College of Pharmacy,, Taif University

Email: info@benthamscience.net

References

  1. Singh, J.A.; Gaffo, A. Gout epidemiology and comorbidities. Semin. Arthritis Rheum., 2020, 50(3), S11-S16. doi: 10.1016/j.semarthrit.2020.04.008 PMID: 32620196
  2. Dalbeth, N.; Bardin, T.; Doherty, M.; Lioté, F.; Richette, P.; Saag, K.G.; So, A.K.; Stamp, L.K.; Choi, H.K.; Terkeltaub, R. Discordant American College of Physicians and international rheumatology guidelines for gout management: Consensus statement of the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). Nat. Rev. Rheumatol., 2017, 13(9), 561-568. doi: 10.1038/nrrheum.2017.126 PMID: 28794514
  3. McCarty, D.J.; Hollander, J.L. Identification of urate crystals in gouty synovial fluid. Ann. Intern. Med., 1961, 54(3), 452-460. doi: 10.7326/0003-4819-54-3-452 PMID: 13773775
  4. FitzGerald, J.D.; Dalbeth, N.; Mikuls, T.; Brignardello-Petersen, R.; Guyatt, G.; Abeles, A.M.; Gelber, A.C.; Harrold, L.R.; Khanna, D.; King, C.; Levy, G.; Libbey, C.; Mount, D.; Pillinger, M.H.; Rosenthal, A.; Singh, J.A.; Sims, J.E.; Smith, B.J.; Wenger, N.S.; Bae, S.S.; Danve, A.; Khanna, P.P.; Kim, S.C.; Lenert, A.; Poon, S.; Qasim, A.; Sehra, S.T.; Sharma, T.S.K.; Toprover, M.; Turgunbaev, M.; Zeng, L.; Zhang, M.A.; Turner, A.S.; Neogi, T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol., 2020, 72(6), 879-895. doi: 10.1002/art.41247 PMID: 32390306
  5. Kuo, C.F.; Grainge, M.J.; Mallen, C.; Zhang, W.; Doherty, M. Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann. Rheum. Dis., 2015, 74(4), 661-667. doi: 10.1136/annrheumdis-2013-204463 PMID: 24431399
  6. te Kampe, R.; Janssen, M.; van Durme, C.; Jansen, T.L.; Boonen, A. Sex differences in the clinical profile among patients with Gout: Cross-sectional analyses of an observational study. J. Rheumatol., 2021, 48(2), 286-292. doi: 10.3899/jrheum.200113 PMID: 32611671
  7. Harrold, L.R.; Etzel, C.J.; Gibofsky, A.; Kremer, J.M.; Pillinger, M.H.; Saag, K.G.; Schlesinger, N.; Terkeltaub, R.; Cox, V.; Greenberg, J.D. Sex differences in gout characteristics: Tailoring care for women and men. BMC Musculoskelet. Disord., 2017, 18(1), 108. doi: 10.1186/s12891-017-1465-9 PMID: 28292303
  8. Hak, A.E.; Curhan, G.C.; Grodstein, F.; Choi, H.K. Menopause, postmenopausal hormone use and risk of incident gout. Ann. Rheum. Dis., 2010, 69(7), 1305-1309. doi: 10.1136/ard.2009.109884 PMID: 19592386
  9. Roman, Y.; Tiirikainen, M.; Prom-Wormley, E. The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort. Clin. Rheumatol., 2020, 39(8), 2387-2392. doi: 10.1007/s10067-020-04994-9 PMID: 32107664
  10. Petersen, K.K.; Siebuhr, A.S.; Graven-Nielsen, T.; Simonsen, O.; Boesen, M.; Gudbergsen, H.; Karsdal, M.; Bay-Jensen, A.C.; Arendt-Nielsen, L. Sensitization and serological biomarkers in knee osteoarthritis patients with different degrees of synovitis. Clin. J. Pain, 2016, 32(10), 841-848. doi: 10.1097/AJP.0000000000000334 PMID: 26633689
  11. Deshmukh, R. Rheumatoid arthritis: Pathophysiology, current therapeutic strategies and recent advances in targeted drug delivery system. Mater. Today Commun., 2023, 35, 105877. doi: 10.1016/j.mtcomm.2023.105877
  12. Pandey, M.; Bajpai, M. Natural remedies for the treatment of arthritis: A review. Med. Plants -. Int. J. Phytomed., 2020, 12(4), 545-554. doi: 10.5958/0975-6892.2020.00067.2
  13. Graessler, J.; Graessler, A.; Unger, S.; Kopprasch, S.; Tausche, A.K.; Kuhlisch, E.; Schroeder, H.E. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population. Arthritis Rheum., 2006, 54(1), 292-300. doi: 10.1002/art.21499 PMID: 16385546
  14. Delgado-Charro, M.B.; Guy, R.H. Effective use of transdermal drug delivery in children. Adv. Drug Deliv. Rev., 2014, 73, 63-82. doi: 10.1016/j.addr.2013.11.014 PMID: 24333231
  15. Bhowmick, M. Sengodan, TJPG Mechanisms, kinetics and mathematical modelling of transdermal permeation-an updated review. Int J Comprehen Pharm., 2013, 4(6), 1-4.
  16. Cevc, G.; Gebauer, D.; Stieber, J.; Schätzlein, A.; Blume, G. Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin. Biochim. Biophys. Acta Biomembr., 1998, 1368(2), 201-215. doi: 10.1016/S0005-2736(97)00177-6 PMID: 9459598
  17. Moreland, L.W.; Schiff, M.H.; Baumgartner, S.W.; Tindall, E.A.; Fleischmann, R.M.; Bulpitt, K.J.; Weaver, A.L.; Keystone, E.C.; Furst, D.E.; Mease, P.J.; Ruderman, E.M.; Horwitz, D.A.; Arkfeld, D.G.; Garrison, L.; Burge, D.J.; Blosch, C.M.; Lange, M.L.; McDonnell, N.D.; Weinblatt, M.E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med., 1999, 130(6), 478-486. doi: 10.7326/0003-4819-130-6-199903160-00004 PMID: 10075615
  18. Beer, J.S.; Stallen, M.; Lombardo, M.V.; Gonsalkorale, K.; Cunningham, W.A.; Sherman, J.W. The Quadruple Process model approach to examining the neural underpinnings of prejudice. Neuroimage, 2008, 43(4), 775-783. doi: 10.1016/j.neuroimage.2008.08.033 PMID: 18809502
  19. Martinon, F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol. Rev., 2010, 233(1), 218-232. doi: 10.1111/j.0105-2896.2009.00860.x PMID: 20193002
  20. Menè, P.; Punzo, G. Uric acid: bystander or culprit in hypertension and progressive renal disease? J. Hypertens., 2008, 26(11), 2085-2092. doi: 10.1097/HJH.0b013e32830e4945 PMID: 18854744
  21. Gabriel, S.E.; Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther., 2009, 11(3), 229. doi: 10.1186/ar2669 PMID: 19519924
  22. Doghramji, P.P.; Wortmann, R.L. Hyperuricemia and gout: new concepts in diagnosis and management. Postgrad. Med., 2012, 124(6), 98-109. doi: 10.3810/pgm.2012.11.2616 PMID: 23322143
  23. Robinson, P.C. Gout – An update of aetiology, genetics, co-morbidities and management. Maturitas, 2018, 118, 67-73. doi: 10.1016/j.maturitas.2018.10.012 PMID: 30415758
  24. Senna, E.R.; De Barros, A.L.; Silva, E.O.; Costa, I.F.; Pereira, L.V.; Ciconelli, R.M.; Ferraz, M.B. Prevalence of rheumatic diseases in Brazil: A study using the COPCORD approach. J. Rheumatol., 2004, 31(3), 594-597. PMID: 14994410
  25. FitzGerald, J.D.; Dalbeth, N.; Mikuls, T.; Brignardello-Petersen, R.; Guyatt, G.; Abeles, A.M.; Gelber, A.C.; Harrold, L.R.; Khanna, D.; King, C.; Levy, G.; Libbey, C.; Mount, D.; Pillinger, M.H.; Rosenthal, A.; Singh, J.A.; Sims, J.E.; Smith, B.J.; Wenger, N.S.; Bae, S.S.; Danve, A.; Khanna, P.P.; Kim, S.C.; Lenert, A.; Poon, S.; Qasim, A.; Sehra, S.T.; Sharma, T.S.K.; Toprover, M.; Turgunbaev, M.; Zeng, L.; Zhang, M.A.; Turner, A.S.; Neogi, T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res., 2020, 72(6), 744-760. doi: 10.1002/acr.24180 PMID: 32391934
  26. Haque, T.; Talukder, M.M.U. Chemical enhancer: A simplistic way to modulate barrier function of the stratum corneum. Adv. Pharm. Bull., 2018, 8(2), 169-179. doi: 10.15171/apb.2018.021 PMID: 30023318
  27. Phatale, V.; Vaiphei, K.K.; Jha, S.; Patil, D.; Agrawal, M.; Alexander, A. Overcoming skin barriers through advanced transdermal drug delivery approaches. J. Control. Release, 2022, 351, 361-380. doi: 10.1016/j.jconrel.2022.09.025 PMID: 36169040
  28. Vitorino, C.; Almeida, A.; Sousa, J.; Lamarche, I.; Gobin, P.; Marchand, S.; Couet, W.; Olivier, J.C.; Pais, A. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: In vitro vs. in vivo studies. Eur. J. Pharm. Biopharm., 2014, 86(2), 133-144. doi: 10.1016/j.ejpb.2013.12.004 PMID: 24333401
  29. Paudel, K.S.; Milewski, M.; Swadley, C.L.; Brogden, N.K.; Ghosh, P.; Stinchcomb, A.L. Challenges and opportunities in dermal/transdermal delivery. Ther. Deliv., 2010, 1(1), 109-131. doi: 10.4155/tde.10.16 PMID: 21132122
  30. Subedi, R.K.; Oh, S.Y.; Chun, M.K.; Choi, H.K. Recent advances in transdermal drug delivery. Arch. Pharm. Res., 2010, 33(3), 339-351. doi: 10.1007/s12272-010-0301-7 PMID: 20361297
  31. Kraft, J.C.; Freeling, J.P.; Wang, Z.; Ho, R.J.Y. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J. Pharm. Sci., 2014, 103(1), 29-52. doi: 10.1002/jps.23773 PMID: 24338748
  32. Dua, J.; Rana, A. Bhandari, AJIJPSR Liposome: Methods of preparation and applications. SCRIBD, 2012, 3, 14-20.
  33. Touitou, E.; Dayan, N.; Bergelson, L.; Godin, B.; Eliaz, M. Ethosomes — novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J. Control. Release, 2000, 65(3), 403-418. doi: 10.1016/S0168-3659(99)00222-9 PMID: 10699298
  34. Cevc, G. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst., 1996, 13(3-4), 257-388. doi: 10.1615/CritRevTherDrugCarrierSyst.v13.i3-4.30 PMID: 9016383
  35. Kuotsu, K.; Karim, K.M.; Mandal, A.S.; Biswas, N.; Guha, A.; Chatterjee, S.; Behera, M. Niosome: A future of targeted drug delivery systems. J. Adv. Pharm. Technol. Res., 2010, 1(4), 374-380. doi: 10.4103/0110-5558.76435 PMID: 22247876
  36. Gupta, R.; Kumar, A. Transfersomes: The ultra-deformable carrier system for non-invasive delivery of drug. Curr. Drug Deliv., 2021, 18(4), 408-420. doi: 10.2174/1567201817666200804105416 PMID: 32753015
  37. Jacob, S.; Nair, A.B.; Shah, J.; Gupta, S.; Boddu, S.H.S.; Sreeharsha, N.; Joseph, A.; Shinu, P.; Morsy, M.A. Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy—an overview on recent advances. Pharmaceutics, 2022, 14(3), 533. doi: 10.3390/pharmaceutics14030533 PMID: 35335909
  38. Duan, Y.; Dhar, A.; Patel, C.; Khimani, M.; Neogi, S.; Sharma, P.; Siva Kumar, N.; Vekariya, R.L. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Advances, 2020, 10(45), 26777-26791. doi: 10.1039/D0RA03491F PMID: 35515778
  39. Kamaly, N.; Yameen, B.; Wu, J.; Farokhzad, O.C. Degradable controlled-release polymers and polymeric nanoparticles: Mechanisms of controlling drug release. Chem. Rev., 2016, 116(4), 2602-2663. doi: 10.1021/acs.chemrev.5b00346 PMID: 26854975
  40. Wang, J.J.; Zeng, Z.W.; Xiao, R.Z.; Xie, T.; Zhou, G.L.; Zhan, X.R.; Wang, S.L. Recent advances of chitosan nanoparticles as drug carriers. Int. J. Nanomedicine, 2011, 6, 765-774. PMID: 21589644
  41. Molavi, F.; Barzegar-Jalali, M.; Hamishehkar, H. Polyester based polymeric nano and microparticles for pharmaceutical purposes: A review on formulation approaches. J. Control. Release, 2020, 320, 265-282. doi: 10.1016/j.jconrel.2020.01.028 PMID: 31962095
  42. Prasad, M.; Lambe, U.P.; Brar, B.; Shah, I. J, M.; Ranjan, K.; Rao, R.; Kumar, S.; Mahant, S.; Khurana, S.K.; Iqbal, H.M.N.; Dhama, K.; Misri, J.; Prasad, G. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world. Biomed. Pharmacother., 2018, 97, 1521-1537. doi: 10.1016/j.biopha.2017.11.026 PMID: 29793315
  43. Singh, R.; Lillard, J.W. Jr Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86(3), 215-223. doi: 10.1016/j.yexmp.2008.12.004 PMID: 19186176
  44. Jain, J.; Arora, S.; Rajwade, J.M.; Omray, P.; Khandelwal, S.; Paknikar, K.M. Silver nanoparticles in therapeutics: Development of an antimicrobial gel formulation for topical use. Mol. Pharm., 2009, 6(5), 1388-1401. doi: 10.1021/mp900056g PMID: 19473014
  45. Koo, O.M.; Rubinstein, I.; Onyuksel, H. Role of nanotechnology in targeted drug delivery and imaging: A concise review. Nanomedicine, 2005, 1(3), 193-212. doi: 10.1016/j.nano.2005.06.004 PMID: 17292079
  46. Rai, V.K.; Mishra, N.; Yadav, K.S.; Yadav, N.P. Nanoemulsion as pharmaceutical carrier for dermal and transdermal drug delivery: Formulation development, stability issues, basic considerations and applications. J. Control. Release, 2018, 270, 203-225. doi: 10.1016/j.jconrel.2017.11.049 PMID: 29199062
  47. Chen, Y.; Feng, X. Gold nanoparticles for skin drug delivery. Int. J. Pharm., 2022, 625, 122122. doi: 10.1016/j.ijpharm.2022.122122 PMID: 35987319
  48. Boisselier, E.; Astruc, D. Gold nanoparticles in nanomedicine: Preparations, imaging, diagnostics, therapies and toxicity. Chem. Soc. Rev., 2009, 38(6), 1759-1782. doi: 10.1039/b806051g PMID: 19587967
  49. Doty, R.C.; Tshikhudo, T.R.; Brust, M.; Fernig, D.G. Extremely stable water-soluble Ag nanoparticles. Chem. Mater., 2005, 17(18), 4630-4635. doi: 10.1021/cm0508017
  50. Batrakova, E.V.; Bronich, T.K.; Vetro, J.A. Nanoparticulates as drug carriers; World Scientific Publishing: Singapore, 2006, p. 756.
  51. Owen, S.C.; Chan, D.P.Y.; Shoichet, M.S. Polymeric micelle stability. Nano Today, 2012, 7(1), 53-65. doi: 10.1016/j.nantod.2012.01.002
  52. Tripathy, S.; Das, M.K. Dendrimers and their applications as novel drug delivery carriers. J. Appl. Pharm. Sci., 2013, 3(9), 142-149.
  53. Ramasamy, S.; Bennet, D.; Kim, S. Drug and bioactive molecule screening based on a bioelectrical impedance cell culture platform. Int. J. Nanomedicine, 2014, 9, 5789-5809. PMID: 25525360
  54. Rostamabadi, H.; Falsafi, S.R.; Jafari, S.M. Nanoencapsulation of carotenoids within lipid-based nanocarriers. J. Control. Release, 2019, 298, 38-67. doi: 10.1016/j.jconrel.2019.02.005 PMID: 30738975
  55. Harwansh, R.K.; Deshmukh, R.; Rahman, M.A. Nanoemulsion: Promising nanocarrier system for delivery of herbal bioactives. J. Drug Deliv. Sci. Technol., 2019, 51, 224-233. doi: 10.1016/j.jddst.2019.03.006
  56. Lim, J.; Lanni, C.; Evarts, E.R.; Lanni, F.; Tilton, R.D.; Majetich, S.A. Magnetophoresis of nanoparticles. ACS Nano, 2011, 5(1), 217-226. doi: 10.1021/nn102383s PMID: 21141977
  57. Suwa, M.; Watarai, H. Magnetoanalysis of micro/nanoparticles: A review. Anal. Chim. Acta, 2011, 690(2), 137-147. doi: 10.1016/j.aca.2011.02.019 PMID: 21435469
  58. Dixit, N.; Bali, V.; Baboota, S.; Ahuja, A.; Ali, J. Iontophoresis - an approach for controlled drug delivery: A review. Curr. Drug Deliv., 2007, 4(1), 1-10. PMID: 17269912
  59. Weaver, J.C.; Chizmadzhev, Y.A. Theory of electroporation: A review. Bioelectrochem. Bioenerg., 1996, 41(2), 135-160. doi: 10.1016/S0302-4598(96)05062-3
  60. Carovac, A.; Smajlovic, F.; Junuzovic, D. Application of ultrasound in medicine. Acta Inform. Med., 2011, 19(3), 168-171. doi: 10.5455/aim.2011.19.168-171 PMID: 23408755
  61. Zhu, D.D.; Wang, Q.L.; Liu, X.B.; Guo, X.D. Rapidly separating microneedles for transdermal drug delivery. Acta Biomater., 2016, 41, 312-319. doi: 10.1016/j.actbio.2016.06.005 PMID: 27265152
  62. Gupta, J.; Gupta, R. Vanshita, Vanshita, Microneedle technology: An insight into recent advancements and future trends in drug and vaccine delivery. Assay Drug Dev. Technol., 2021, 19(2), 97-114. doi: 10.1089/adt.2020.1022 PMID: 33297823
  63. Unver, N.; Odabas, S.; Demirel, G.B.; Gul, O.T. Hollow microneedle array fabrication using a rational design to prevent skin clogging in transdermal drug delivery. J. Mater. Chem. B Mater. Biol. Med., 2022, 10(41), 8419-8431. doi: 10.1039/D2TB01648F PMID: 36218040
  64. Hao, Y.; Li, W.; Zhou, X.; Yang, F.; Qian, Z. Microneedles-based transdermal drug delivery systems: A review. J. Biomed. Nanotechnol., 2017, 13(12), 1581-1597. doi: 10.1166/jbn.2017.2474 PMID: 29490749
  65. Menon, I.; Bagwe, P.; Gomes, K.B.; Bajaj, L.; Gala, R.; Uddin, M.N.; D’Souza, M.J.; Zughaier, S.M. Microneedles: A new generation vaccine delivery system. Micromachines, 2021, 12(4), 435. doi: 10.3390/mi12040435 PMID: 33919925
  66. Wilson, L.; Saseen, J.J. Gouty arthritis: A review of acute management and prevention. Pharmacotherapy, 2016, 36(8), 906-922. doi: 10.1002/phar.1788 PMID: 27318031
  67. Ahern, M.J.; Reid, C.; Gordon, T.P. McCREDlE, M.; Brooks, P.M.; Jones, M. Does colchicine work? The results of the first controlled study in acute gout. Aust. N. Z. J. Med., 1987, 17(3), 301-304. doi: 10.1111/j.1445-5994.1987.tb01232.x PMID: 3314832
  68. Pascual, E.; Sivera, F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann. Rheum. Dis., 2007, 66(8), 1056-1058. doi: 10.1136/ard.2006.060368 PMID: 17223663
  69. Dalbeth, N.; Lauterio, T.J.; Wolfe, H.R. Mechanism of action of colchicine in the treatment of gout. Clin. Ther., 2014, 36(10), 1465-1479. doi: 10.1016/j.clinthera.2014.07.017 PMID: 25151572
  70. Kean, W.F.; Buchanan, W.W. The use of NSAIDs in rheumatic disorders 2005: A global perspective. Inflammopharmacology, 2005, 13(4), 343-370. doi: 10.1163/156856005774415565 PMID: 16354389
  71. Varrassi, G.; Alon, E.; Bagnasco, M.; Lanata, L.; Mayoral-Rojals, V.; Paladini, A.; Pergolizzi, J.V.; Perrot, S.; Scarpignato, C.; Tölle, T. Towards an effective and safe treatment of inflammatory pain: A delphi-guided expert consensus. Adv. Ther., 2019, 36(10), 2618-2637. doi: 10.1007/s12325-019-01053-x PMID: 31485978
  72. Hainer, B.L.; Matheson, E.; Wilkes, R.T. Diagnosis, treatment, and prevention of gout. Am. Fam. Physician, 2014, 90(12), 831-836. PMID: 25591183
  73. Pillinger, M.H.; Mandell, B.F. Therapeutic approaches in the treatment of gout. Semin. Arthritis Rheum., 2020, 50(3), S24-S30. doi: 10.1016/j.semarthrit.2020.04.010 PMID: 32620199
  74. Lieberman, J.A., III Treatment and prophylaxis of gout flare in the clinic: An office-based approach to gout management. Postgrad. Med., 2011, 123(6), 151-165. doi: 10.3810/pgm.2011.11.2505 PMID: 22104464
  75. Brucato, A.; Cianci, F.; Carnovale, C. Management of hyperuricemia in asymptomatic patients: A critical appraisal. Eur. J. Intern. Med., 2020, 74, 8-17. doi: 10.1016/j.ejim.2020.01.001 PMID: 31952982
  76. Chen, L.; Wang, Y.; Sun, L.; Yan, J.; Mao, H.Q. Nanomedicine strategies for anti‐inflammatory treatment of noninfectious Arthritis. Adv. Healthc. Mater., 2021, 10(11), 2001732. doi: 10.1002/adhm.202001732 PMID: 33870656
  77. Torchilin, V.P. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat. Rev. Drug Discov., 2014, 13(11), 813-827. doi: 10.1038/nrd4333 PMID: 25287120
  78. Aslam, H.; Shukrullah, S.; Naz, M.Y.; Fatima, H.; Hussain, H.; Ullah, S.; Assiri, M.A. Current and future perspectives of multifunctional magnetic nanoparticles based controlled drug delivery systems. J. Drug Deliv. Sci. Technol., 2022, 67, 102946. doi: 10.1016/j.jddst.2021.102946
  79. Lippacher, A.; Müller, R.H.; Mäder, K. Preparation of semisolid drug carriers for topical application based on solid lipid nanoparticles. Int. J. Pharm., 2001, 214(1-2), 9-12. doi: 10.1016/S0378-5173(00)00623-2 PMID: 11282228
  80. Lee, S.M.; Kim, H.J.; Ha, Y.J.; Park, Y.N.; Lee, S.K.; Park, Y.B.; Yoo, K.H. Targeted chemo-photothermal treatments of rheumatoid arthritis using gold half-shell multifunctional nanoparticles. ACS Nano, 2013, 7(1), 50-57. doi: 10.1021/nn301215q PMID: 23194301
  81. Kesharwani, D.; Paliwal, R.; Satapathy, T.; Paul, S.D. Rheumatiod Arthritis: An updated overview of latest therapy and drug delivery. J. Pharmacopuncture, 2019, 22(4), 210-224. doi: 10.3831/KPI.2019.22.029 PMID: 31970018
  82. Satya, P.M.; Padmaja, N.V.; Nadiya, S.; Masthani, S.; Satya, A.K. A review on role of nanoparticles in rheumatoid arthritis therapy. Indian J. Res. Pharm. Biotechnol., 2016, 4(6), 255.
  83. Lansdown, A.B.G. GOLD: Human exposure and update on toxic risks. Crit. Rev. Toxicol., 2018, 48(7), 596-614. doi: 10.1080/10408444.2018.1513991 PMID: 31851875
  84. Lee, H.; Lee, M.Y.; Bhang, S.H.; Kim, B.S.; Kim, Y.S.; Ju, J.H.; Kim, K.S.; Hahn, S.K. Hyaluronate-gold nanoparticle/tocilizumab complex for the treatment of rheumatoid arthritis. ACS Nano, 2014, 8(5), 4790-4798. doi: 10.1021/nn500685h PMID: 24730974
  85. Homma, A.; Sato, H.; Okamachi, A.; Emura, T.; Ishizawa, T.; Kato, T.; Matsuura, T.; Sato, S.; Tamura, T.; Higuchi, Y.; Watanabe, T.; Kitamura, H.; Asanuma, K.; Yamazaki, T.; Ikemi, M.; Kitagawa, H.; Morikawa, T.; Ikeya, H.; Maeda, K.; Takahashi, K.; Nohmi, K.; Izutani, N.; Kanda, M.; Suzuki, R. Novel hyaluronic acid–methotrexate conjugates for osteoarthritis treatment. Bioorg. Med. Chem., 2009, 17(13), 4647-4656. doi: 10.1016/j.bmc.2009.04.063 PMID: 19457673
  86. Zheng, Z.; Sun, Y.; Liu, Z.; Zhang, M.; Li, C.; Cai, H. The effect of curcumin and its nanoformulation on adjuvant-induced arthritis in rats. Drug Des. Devel. Ther., 2015, 9, 4931-4942. PMID: 26345159
  87. Sailaja, A.K.; Lola, V.S. Formulation of mefenamic acid loaded polymeric nanoparticles for the treatment of rheumatoid arthritis. J. Bionanosci, 2018, 12(2), 177-183. doi: 10.1166/jbns.2018.1525
  88. Yasamineh, S.; Yasamineh, P.; Ghafouri Kalajahi, H.; Gholizadeh, O.; Yekanipour, Z.; Afkhami, H.; Eslami, M.; Hossein Kheirkhah, A.; Taghizadeh, M.; Yazdani, Y.; Dadashpour, M. A state-of-the-art review on the recent advances of niosomes as a targeted drug delivery system. Int. J. Pharm., 2022, 624, 121878. doi: 10.1016/j.ijpharm.2022.121878 PMID: 35636629
  89. Ye, J.; Wang, Q.; Zhou, X.; Zhang, N. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis. Int. J. Pharm., 2008, 352(1-2), 273-279. doi: 10.1016/j.ijpharm.2007.10.014 PMID: 18054182
  90. Boechat, A.L.; de Oliveira, C.P.; Tarragô, A.M.; da Costa, A.G.; Malheiro, A.; Guterres, S.S.; Pohlmann, A.R. Methotrexate-loaded lipid-core nanocapsules are highly effective in the control of inflammation in synovial cells and a chronic arthritis model. Int. J. Nanomedicine, 2015, 10, 6603-6614. PMID: 26543364
  91. Zhou, M.; Hou, J.; Zhong, Z.; Hao, N.; Lin, Y.; Li, C. Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy. Drug Deliv., 2018, 25(1), 716-722. doi: 10.1080/10717544.2018.1447050 PMID: 29516758
  92. Sahin, N.O. Niosomes as Nanocarrier SystemsNanomaterials and Nanosystems for Biomedical Applications; Springer Nature: Switzerland, 2007.
  93. Nasra, S.; Bhatia, D.; Kumar, A. Recent advances in nanoparticle-based drug delivery systems for rheumatoid arthritis treatment. Nanoscale Adv., 2022, 4(17), 3479-3494. doi: 10.1039/D2NA00229A PMID: 36134349
  94. Akbarzadeh, A.; Rezaei-Sadabady, R.; Davaran, S.; Joo, S.W.; Zarghami, N.; Hanifehpour, Y.; Samiei, M.; Kouhi, M.; Nejati-Koshki, K. Liposome: Classification, preparation, and applications. Nanoscale Res. Lett., 2013, 8(1), 102. doi: 10.1186/1556-276X-8-102 PMID: 23432972
  95. van den Hoven, J.M.; Van Tomme, S.R.; Metselaar, J.M.; Nuijen, B.; Beijnen, J.H.; Storm, G. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol. Pharm., 2011, 8(4), 1002-1015. doi: 10.1021/mp2000742 PMID: 21634436
  96. Prabhu, P.; Shetty, R.; Koland, M.; Bhat, V.K.; Vijayalakshmi, K.K.; Nairy, H.M.; Shetty, N.G. Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity. Int. J. Nanomedicine, 2012, 7, 177-186. doi: 10.2147/IJN.S25310 PMID: 22275833
  97. Gottschalk, O.; Metz, P.; Dao Trong, M.L.; Altenberger, S.; Jansson, V.; Mutschler, W.; Schmitt-Sody, M. Therapeutic effect of methotrexate encapsulated in cationic liposomes (EndoMTX) in comparison to free methotrexate in an antigen-induced arthritis study in vivo. Scand. J. Rheumatol., 2015, 44(6), 456-463. doi: 10.3109/03009742.2015.1030448 PMID: 26114440
  98. Kapoor, B.; Singh, S.K.; Gulati, M.; Gupta, R.; Vaidya, Y. Application of liposomes in treatment of rheumatoid arthritis: quo vadis. Sci. World J., 2014, 2014, 1-17. doi: 10.1155/2014/978351 PMID: 24688450
  99. Ghosh, S.; Mukherjee, B.; Chaudhuri, S.; Roy, T.; Mukherjee, A.; Sengupta, S. Methotrexate aspasomes against rheumatoid arthritis: Optimized hydrogel loaded liposomal formulation with in vivo evaluation in wistar rats. AAPS PharmSciTech, 2018, 19(3), 1320-1336. doi: 10.1208/s12249-017-0939-2 PMID: 29340978
  100. Kumari, A.; Yadav, S.K.; Yadav, S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B Biointerfaces, 2010, 75(1), 1-18. doi: 10.1016/j.colsurfb.2009.09.001 PMID: 19782542
  101. Ahmad, Z.; Shah, A.; Siddiq, M.; Kraatz, H-B. Polymeric micelles as drug delivery vehicles. RSC Advances, 2014, 4(33), 17028-17038. doi: 10.1039/C3RA47370H
  102. Sethi, V.; Rubinstein, I.; Kuzmis, A.; Kastrissios, H.; Artwohl, J.; Onyuksel, H. Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol. Pharm., 2013, 10(2), 728-738. doi: 10.1021/mp300539f PMID: 23211088
  103. Gomariz, R.P.; Juarranz, Y.; Carrión, M.; Pérez-García, S.; Villanueva-Romero, R.; González-Álvaro, I.; Gutiérrez-Cañas, I.; Lamana, A.; Martínez, C. An overview of VPAC receptors in rheumatoid arthritis: Biological role and clinical significance. Front. Endocrinol., 2019, 10, 729. doi: 10.3389/fendo.2019.00729 PMID: 31695683
  104. Li, P.; Zheng, Y.; Chen, X. Drugs for autoimmune inflammatory diseases: From small molecule compounds to Anti-TNF biologics. Front. Pharmacol., 2017, 8, 460. doi: 10.3389/fphar.2017.00460 PMID: 28785220
  105. Gupta, A.; Eral, H.B.; Hatton, T.A.; Doyle, P.S. Nanoemulsions: Formation, properties and applications. Soft Matter, 2016, 12(11), 2826-2841. doi: 10.1039/C5SM02958A PMID: 26924445
  106. Singh, Y.; Meher, J.G.; Raval, K.; Khan, F.A.; Chaurasia, M.; Jain, N.K.; Chourasia, M.K. Nanoemulsion: Concepts, development and applications in drug delivery. J. Control. Release, 2017, 252, 28-49. doi: 10.1016/j.jconrel.2017.03.008 PMID: 28279798
  107. Cao, M.; Ren, L.; Chen, G. Formulation optimization and ex vivo and in vivo evaluation of celecoxib microemulsion-based gel for transdermal delivery. AAPS PharmSciTech, 2017, 18(6), 1960-1971. doi: 10.1208/s12249-016-0667-z PMID: 27914040
  108. Zhang, H.; Zhai, Y.; Wang, J.; Zhai, G. New progress and prospects: The application of nanogel in drug delivery. Mater. Sci. Eng. C, 2016, 60, 560-568. doi: 10.1016/j.msec.2015.11.041 PMID: 26706564
  109. Ghasemiyeh, P.; Mohammadi-Samani, S. Potential of nanoparticles as permeation enhancers and targeted delivery options for skin: Advantages and disadvantages. Drug Des. Devel. Ther., 2020, 14, 3271-3289. doi: 10.2147/DDDT.S264648 PMID: 32848366
  110. Allegrini, S.; Garcia-Gil, M.; Pesi, R.; Camici, M.; Tozzi, M.G. The good, the bad and the new about uric acid in cancer. Cancers, 2022, 14(19), 4959. doi: 10.3390/cancers14194959 PMID: 36230882
  111. Ramadon, D.; McCrudden, M.T.C.; Courtenay, A.J.; Donnelly, R.F. Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Deliv. Transl. Res., 2022, 12(4), 758-791. doi: 10.1007/s13346-021-00909-6 PMID: 33474709
  112. Engel, B.; Just, J.; Bleckwenn, M.; Weckbecker, K. Treatment options for Gout. Dtsch. Arztebl. Int., 2017, 114(13), 215-222. PMID: 28434436
  113. Ariamoghaddam, A.; Ebrahimi-Hosseinzadeh, B.; Hatamian-Zarmi, A.; Sahraeian, R. In vivo anti-obesity efficacy of curcumin loaded nanofibers transdermal patches in high-fat diet induced obese rats. Mater. Sci. Eng. C, 2018, 92, 161-171. doi: 10.1016/j.msec.2018.06.030 PMID: 30184739
  114. Hewlings, S.; Kalman, D. Curcumin: A review of its effects on human health. Foods, 2017, 6(10), 92. doi: 10.3390/foods6100092 PMID: 29065496
  115. Zhang, Y.; Zhang, N.; Song, H.; Li, H.; Wen, J.; Tan, X.; Zheng, W. Design, characterization and comparison of transdermal delivery of colchicine via borneol-chemically-modified and borneol-physically-modified ethosome. Drug Deliv., 2019, 26(1), 70-77. doi: 10.1080/10717544.2018.1559258 PMID: 30744424
  116. Samadi, F.; Kahrizi, M.S.; Heydari, F.; Arefnezhad, R.; Roghani-Shahraki, H.; Mokhtari Ardekani, A.; Rezaei-Tazangi, F. Quercetin and osteoarthritis: A mechanistic review on the present documents. Pharmacology, 2022, 107(9-10), 464-471. doi: 10.1159/000525494 PMID: 35793647
  117. Li, Z.; Fang, X.; Yu, D. Transdermal drug delivery systems and their use in obesity treatment. Int. J. Mol. Sci., 2021, 22(23), 12754. doi: 10.3390/ijms222312754 PMID: 34884558
  118. Abramoff, B.; Caldera, F.E. Osteoarthritis. Med. Clin. North Am., 2020, 104(2), 293-311. doi: 10.1016/j.mcna.2019.10.007 PMID: 32035570
  119. Park, J.; Mendy, A.; Vieira, E.R. Various types of arthritis in the united states: Prevalence and age-related trends from 1999 to 2014. Am. J. Public Health, 2018, 108(2), 256-258. doi: 10.2105/AJPH.2017.304179 PMID: 29267054
  120. Smolen, J.S.; Landewé, R.B.M.; Bijlsma, J.W.J.; Burmester, G.R.; Dougados, M.; Kerschbaumer, A.; McInnes, I.B.; Sepriano, A.; van Vollenhoven, R.F.; de Wit, M.; Aletaha, D.; Aringer, M.; Askling, J.; Balsa, A.; Boers, M.; den Broeder, A.A.; Buch, M.H.; Buttgereit, F.; Caporali, R.; Cardiel, M.H.; De Cock, D.; Codreanu, C.; Cutolo, M.; Edwards, C.J.; van Eijk-Hustings, Y.; Emery, P.; Finckh, A.; Gossec, L.; Gottenberg, J.E.; Hetland, M.L.; Huizinga, T.W.J.; Koloumas, M.; Li, Z.; Mariette, X.; Müller-Ladner, U.; Mysler, E.F.; da Silva, J.A.P.; Poór, G.; Pope, J.E.; Rubbert-Roth, A.; Ruyssen-Witrand, A.; Saag, K.G.; Strangfeld, A.; Takeuchi, T.; Voshaar, M.; Westhovens, R.; van der Heijde, D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann. Rheum. Dis., 2020, 79(6), 685-699. doi: 10.1136/annrheumdis-2019-216655 PMID: 31969328
  121. Love, B.L.; Barrons, R.; Veverka, A.; Snider, K.M. Urate-lowering therapy for gout: Focus on febuxostat. Pharmacotherapy, 2010, 30(6), 594-608. doi: 10.1592/phco.30.6.594 PMID: 20500048
  122. Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; Kaldas, M.; Gogia, M.; Perez-Ruiz, F.; Taylor, W.; Lioté, F.; Choi, H.; Singh, J.A.; Dalbeth, N.; Kaplan, S.; Niyyar, V.; Jones, D.; Yarows, S.A.; Roessler, B.; Kerr, G.; King, C.; Levy, G.; Furst, D.E.; Edwards, N.L.; Mandell, B.; Schumacher, H.R.; Robbins, M.; Wenger, N.; Terkeltaub, R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res., 2012, 64(10), 1431-1446. doi: 10.1002/acr.21772 PMID: 23024028
  123. Mease, P.J.; Antoni, C.E.; Gladman, D.D.; Taylor, W.J. Psoriatic arthritis assessment tools in clinical trials. Ann. Rheum. Dis., 2005, 64(Suppl. 2), 49-54. doi: 10.1136/ard.2004.034165
  124. Cipolletta, E.; Di Battista, J.; Di Carlo, M.; Di Matteo, A.; Salaffi, F.; Grassi, W.; Filippucci, E. Sonographic estimation of monosodium urate burden predicts the fulfillment of the 2016 remission criteria for gout: A 12-month study. Arthritis Res. Ther., 2021, 23(1), 185. doi: 10.1186/s13075-021-02568-x PMID: 34243813
  125. So, A.K.; Martinon, F. Inflammation in gout: Mechanisms and therapeutic targets. Nat. Rev. Rheumatol., 2017, 13(11), 639-647. doi: 10.1038/nrrheum.2017.155 PMID: 28959043
  126. Genovese, M.C.; Smolen, J.S.; Takeuchi, T.; Burmester, G.; Brinker, D.; Rooney, T.P.; Zhong, J.; Daojun, M.; Saifan, C.; Cardoso, A.; Issa, M.; Wu, W-S.; Winthrop, K.L. Safety profile of baricitinib for the treatment of rheumatoid arthritis over a median of 3 years of treatment: An updated integrated safety analysis. Lancet Rheumatol., 2020, 2(6), e347-e357. doi: 10.1016/S2665-9913(20)30032-1
  127. Santos, L.F.; Correia, I.J.; Silva, A.S.; Mano, J.F. Biomaterials for drug delivery patches. Eur. J. Pharm. Sci., 2018, 118, 49-66. doi: 10.1016/j.ejps.2018.03.020 PMID: 29572160
  128. Papadopoulos, C.G.; Gartzonikas, I.K.; Pappa, T.K.; Markatseli, T.E.; Migkos, M.P.; Voulgari, P.V.; Drosos, A.A. Eight-year survival study of first-line tumour necrosis factor α inhibitors in rheumatoid arthritis: Real-world data from a university centre registry. Rheumatol. Adv. Pract., 2019, 3(1), rkz007. doi: 10.1093/rap/rkz007 PMID: 31431995
  129. Mahmood, A.; Rapalli, V.K.; Waghule, T.; Gorantla, S.; Singhvi, G. Luliconazole loaded lyotropic liquid crystalline nanoparticles for topical delivery: QbD driven optimization, in vitro characterization and dermatokinetic assessment. Chem. Phys. Lipids, 2021, 234, 105028. doi: 10.1016/j.chemphyslip.2020.105028 PMID: 33309940
  130. Shang, H.; Younas, A.; Zhang, N. Recent advances on transdermal delivery systems for the treatment of arthritic injuries: From classical treatment to nanomedicines. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2022, 14(3), e1778. doi: 10.1002/wnan.1778 PMID: 35112483
  131. Zhang, M.; Cui, R.; Zhou, Y.; Ma, Y.; Jin, Y.; Gou, X.; Yang, J.; Wu, X. Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology, 2023, 483, 153387. doi: 10.1016/j.tox.2022.153387 PMID: 36464070
  132. Gherghina, M.E.; Peride, I.; Tiglis, M.; Neagu, T.P.; Niculae, A.; Checherita, I.A. Uric acid and oxidative stress—relationship with cardiovascular, metabolic, and renal impairment. Int. J. Mol. Sci., 2022, 23(6), 3188. doi: 10.3390/ijms23063188 PMID: 35328614
  133. Hussain, A.; Singh, S.; Sharma, D.; Webster, T.; Shafaat, K.; Faruk, A. Elastic liposomes as novel carriers: Recent advances in drug delivery. Int. J. Nanomedicine, 2017, 12, 5087-5108. doi: 10.2147/IJN.S138267 PMID: 28761343
  134. Romero, E.L.; Morilla, M.J. Ultradeformable phospholipid vesicles as a drug delivery system: A review. Research and Reports in Transdermal Drug Delivery, 2015, 2015, 55-69. doi: 10.2147/RRTD.S50370
  135. Chaturvedi, S.; Garg, A. An insight of techniques for the assessment of permeation flux across the skin for optimization of topical and transdermal drug delivery systems. J. Drug Deliv. Sci. Technol., 2021, 62, 102355. doi: 10.1016/j.jddst.2021.102355
  136. Chaurasiya, C.; Gupta, J.; Kumar, S. Herbal nanoemulsion in topical drug delivery and skin disorders: Green approach. J. Rep. Pharm. Sci., 2021, 10(2), 171-181. doi: 10.4103/jrptps.JRPTPS_64_20

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers